Increased risk of lung cancer, heart attack from radiotherapy for breast cancer patients who smoke

In a new study published in the Journal of Clinical Oncology, researchers found that smokers treated for breast cancer have a higher risk than non-smokers when it comes to developing lung cancer or heart attack as a result of radiotherapy.

Researchers used data from a worldwide study by the Early Breast Cancer Trialists’ Collaborative Group of the lung and heart radiation doses and risks among women with breast cancer.

Data suggests that for non-smokers, the long-term risk of death from lung cancer or heart attack caused by radiation is only 0.5 percent. However for smokers, the risk is about 5 percent.

The team of researchers also took into account that modern breast care radiotherapy techniques have improved over the years, so they used recent literature when looking at how radiotherapy is being targeted today.

"This research highlights that breast cancer patients who smoke need to be offered help and support in order to try and quit to minimise any risks from their treatment,” said Julie Sharp, head of health information at London's Cancer Research UK, in a statement. “It's important to remember that modern day radiotherapy techniques have been refined and improved to make sure it is targeted and effective while reducing the risk of side effects."

Jodelle joined TriMed Media Group in 2016 as a senior writer, focusing on content for Radiology Business and Health Imaging. After receiving her master's from DePaul University, she worked as a news reporter and communications specialist.

Around the web

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.